Overview

Sensoril(Ashwaganhda)for Bipolar Disorder

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators hypothesis is that oral Sensoril® (as compared to placebo) will enhance cognitive abilities (specifically measures of attention, executive function, working memory, and visuospatial ability) in persons with bipolar disorder. Secondarily, the investigators hypothesize there will be secondary improvements in residual mood/anxiety symptoms, and metabolic indices, if impaired (fasting blood glucose and lipids). The investigators aim to test these hypotheses by conducting a randomized, placebo controlled, add on treatment trial of Sensoril® (added to existing mood stabilizer treatment) recruiting 60 subjects with DSM IV-TR bipolar disorder for a period of 8 weeks. Measures of cognition, psychopathology and laboratory indices will be utilized for evaluating primary and secondary outcomes, along with safety assessments.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Alliance for Research on Schizophrenia and Depression
Criteria
Inclusion Criteria:

- DSMIV-TR diagnosis of Bipolar Disorder

- Ages 18 to 65

- Men or Women

- 8th grade education or greater

- Able to provide competent written informed consent

- Current main mood stabilizer and mood status (YMRS and MADRS scores less than or equal
to 10) are stable for greater than or equal to 4 weeks by history.

Exclusion Criteria:

- Medically unstable conditions

- Known allergy to Sensoril® (or Ashwagandha)

- Current cognitive decline is attributable to a diagnosis of dementia or other
neurological disorder

- Pregnant or lactating women

- Mini-mental score (MMSE) less than or equal to 23

- Currently receiving donepezil, rivastigamine, or galatamine, or memantine or any
marketed agent for slowing memory loss in dementia

- Abnormal clinical thyroid status

- Currently (or within past 2 weeks) receiving St. John's Wort, Gingko or Omega-3